Newborn screening for cystic fibrosis

Lancet Respir Med. 2016 Aug;4(8):653-661. doi: 10.1016/S2213-2600(16)00053-9. Epub 2016 Apr 1.


Since the late 1970s when the potential of the immunoreactive trypsinogen assay for early identification of infants with cystic fibrosis was first recognised, the performance of newborn blood spot screening (NBS) has been continually assessed and its use has gradually expanded. NBS for cystic fibrosis is a cost-effective strategy and, if standards of care are fully implemented and robust management pathways are in place, has a positive effect on clinical outcomes. In the past decade, NBS has undergone rapid expansion and an unprecedented number of infants with cystic fibrosis have access to early diagnosis and care. Cystic fibrosis NBS has now moved on from the development phase and is entering an era of consolidation. In the future, research should focus on the rationalisation and optimisation of existing programmes, with particular attention to bioethical implications such as unwanted detection of carriers and inconclusive diagnoses.

Publication types

  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Cystic Fibrosis / diagnosis*
  • Cystic Fibrosis / economics
  • Early Diagnosis
  • Female
  • Humans
  • Immunoenzyme Techniques / economics
  • Immunoenzyme Techniques / methods
  • Immunoenzyme Techniques / trends*
  • Infant, Newborn
  • Male
  • Neonatal Screening / economics
  • Neonatal Screening / methods
  • Neonatal Screening / trends*
  • Trypsinogen


  • Trypsinogen